| 摘要 |
PURPOSE:An antitumor agent that contains Staphylococcus leukocidine as an active ingredient, thus being effective to leukemia, particularly human myelogenous leukemia, because it dissolves myelogenous leukemia cells without great adverse effects on normal multinuclear leukocytes. CONSTITUTION:The objective antitumor agent is obtained by using Staphylococcus leukocidine as an active ingredient. Staphylococcus leukocidine is obtained from a disease-causative Staphylococcus, e.g., Staphylococcus aureus V8 strain, and a toxin having an action of leukocytolysis composed of leukocidine S and leukocidine F. Its antitumor action is caused by the synergism of them and shows very high sensitivity to cells of leukemia, especially human myelogenous leukemia. The difference in sensitivity to a variety of cells depends on the activity of phospholipase A2 in leukocyte membranes developed by the connection of leukocidine S to receptor gangliosie GM1.
|
